AUTHORS
Niels Weinhold, PhD, Marc-Steffen Steffen Raab, MD2, K. Martin Kortüm, MD3, Jan Kronke, MD4, Roland Fenk, MD5, Katja Weisel, MD6, Christoph Schaefers, MD7, Lilli Podola8, Uta Bertsch, MD9, Alexander Brobeil10, Julia Mersi, MD11, Stefanie Huhn, PhD12, Philipp Reichert, PhD13, Michael Hundemer, MD14, Stephan Bohl, MD15, Elias K. Mai, MD16, Natalie Schub17, Johannes Waldschmidt, MD18, Florian Bassermann, MD19, Carsten Mueller-Tidow, MD20, Christoph Heuck, MD21, Josephine Khan22, Elena Ershova23, Bas D. Koster, MD, PhD24, Monika Engelhardt, MD25, Mathias Hänel, MD26, Hans-Juergen Salwender, MD27, Raphael Teipel28, Hartmut Goldschmidt, MD29, Hermann Einsele, MD, PhD30, Leo Rasche Jr, MD31
AFFILIATIONS
1 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
2 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
3 University Hospital of Würzburg, Würzburg, Germany
4 Charité – Universitätsmedizin Berlin, Berlin, Germany
5 University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
9 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
10 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
11 University Hospital of Würzburg, Würzburg, Germany
12 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
13 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
14 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
15 Charité – Universitätsmedizin Berlin, Berlin, Germany
16 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
17 Universitätsklinikum Schleswig-Holstein (UKSH) Campus Kiel, Kiel, Germany
18 University Hospital of Würzburg, Würzburg, Germany
19 TUM Klinikum, Technische Universität München, München, Germany
20 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
21 Johnson & Johnson, Spring House, Pennsylvania, United States
22 Johnson & Johnson, High Wycombe, United Kingdom
23 Johnson & Johnson, Beerse, Belgium
24 Johnson & Johnson, Leiden, Netherlands
25 Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
26 Klinikum Chemnitz, Chemnitz, Germany
27 Asklepios Klinik Altona and Asklepios Klinik St. Georg, Hamburg, Germany
28 Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany
29 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
30 University Hospital of Würzburg, Würzburg, Germany
31 University Hospital of Würzburg, Würzburg, Germany
ABSTRACT
Introduction: The BCMA×CD3 bispecific antibody teclistamab (Tec) induces deep and durable responses in heavily-pretreated multiple myeloma (MM). Based on these findings, we hypothesized that early incorporation of Tec into a multiagent frontline strategy could eradicate all tumor subclones and enable cure. To test this concept, we initiated the phase 2 GMMG-HD10/DSMM-XX (MajesTEC-5; NCT05695508) trial evaluating Tec in combination with established daratumumab (D) based induction regimens, followed by high-dose melphalan, autologous stem cell transplantation, and maintenance with Tec and D in newly diagnosed transplant-eligible MM patients (TE NDMM). We recently reported MRD-negativity rates in the first three cohorts, achieving 100% after induction in evaluable patients (Raab et al., Nature Medicine 2026). However, early deep responses do not necessarily imply durable disease eradication, in particular in patients with high-risk disease. Sustained MRD negativity has emerged as a more meaningful surrogate for long-term outcome. Here, we report the rate of sustained MRD negativity in the first three cohorts of MajesTEC-5.
Methods: Fifty patients were enrolled in arms A (Tec-DRd, n=10), A1 (Tec-DRd, n=20), and B (Tec-DVRd, n=20). One patient in arm B did not receive study treatment, and two patients (one in arm A1 and one in arm B) discontinued all study treatment before completing induction because of refusal of further treatment. Consequently, 47 patients were included in the sustained MRD analysis. Details of the induction regimen and ASCT have been reported previously. During maintenance, patients received subcutaneous Tec and D for 18 cycles, with oral lenalidomide added in arm A. After at least 1 year of continuous MRD negativity from the first documented MRD-negative assessment, patients could elect to discontinue maintenance therapy. Per protocol, MRD was assessed by next-generation flow cytometry (sensitivity, 10?5) after induction cycles 3 and 6, after ASCT at the start of maintenance, and every 6 months during maintenance and follow-up. High-risk status according to the IMS/IMWG consensus was determined by whole-genome sequencing and/or FISH.
Results: At the data cutoff (July 10th 2026), no MRD conversion or progressive disease event had been observed in patients from the first three cohorts, and protocol-defined MRD assessments are ongoing. Consequently, the reported duration of sustained MRD reflects the current duration of follow-up rather than MRD relapse. Overall, 44 patients (94%) had already achieved ≥12 months of sustained MRD negativity, and 41 (87%) had maintained MRD negativity for ≥18 months. At the current follow-up, the median duration of sustained MRD was 25 months (range, 5–33). Of the three patients with <12 months of sustained MRD negativity, one died from an opportunistic viral infection during maintenance, while two declined bone marrow aspiration after 6 months of maintenance. All 47 patients also achieved a complete response (CR). The duration of sustained MRD-negative CR was slightly shorter than sustained MRD negativity (median, 20 months; range, 5–33), mainly because of persistent immunofixation positivity, likely reflecting the prolonged half-life of IgG and/or delayed resolution of paraskeletal plasmacytomas. Among patients with high-risk disease (n=13, 28%), the median duration of sustained MRD was 24 months (range, 5–32). Importantly, this included patients with ultra-high-risk disease, defined by ≥3 high-risk chromosomal abnormalities and/or tumor suppressor gene inactivation. Notably, four high-risk patients, who elected to discontinue study treatment after ≥12 months of sustained MRD negativity, remain negative after 6 (n=2) or 12 months (n=2) of further follow-up, including one patient with biallelic TP53 inactivation and gain(1q).
Conclusions: Tec-based induction and maintenance therapy resulted in high rates of sustained MRD negativity, including in patients with high-risk disease. Sustained MRD negativity was maintained even after treatment discontinuation. To date, no MRD conversion has been observed. Longer follow-up is required to determine whether this treatment has the potential to alter the natural history of MM by achieving a functional cure.
DISCLOSURES
Niels Weinhold, PhD: J&J - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)